Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 7Unknown 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 23Myeloid 17Sarcoma 9Gastrointestinal 7Lymphoid 6Tumor-Agnostic 2Other solid neoplasm 2Dermatologic 2Thoracic 1Head & Neck 1CNS 1

Conditions

Relapsed Pediatric Solid Tumor 1Mesothelioma 1

Interventions

Injections 17Cisplatin 15Carboplatin 15Oxaliplatin 11Gemcitabine 11pembrolizumab 8Capecitabine 8toripalimab 7Paclitaxel 7Etoposide 7Cyclophosphamide 7Pemetrexed 6Irinotecan 6Drug Therapy 6spartalizumab 5fludarabine 5camrelizumab 5Vincristine 5Radiotherapy 5Leucovorin 5tislelizumab 4apatinib 4anlotinib 4Interleukin-2 4Immune Checkpoint Inhibitors 4Granulocyte-Macrophage Colony-Stimulating Factor 4Fluorouracil 4Docetaxel 4Bevacizumab 4tremelimumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Imatinib Mesylate × Other solid neoplasm × Clear all
NCT02638428 2020-03-19

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Samsung Medical Center

Phase 2 Unknown
90 enrolled
Other solid neoplasm

Relapsed Pediatric Solid Tumor

NCT00551252 2007-10-30

A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma

Gruppo Italiano MEsotelioma

Phase 2 Unknown
56 enrolled
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡